3222-50-2 Usage
Description
4-Methylnicotinic acid, also known as 4-methylpyridine-3-carboxylic acid, is an organic compound derived from nicotinic acid. It is characterized by a white powder appearance and possesses a methyl group attached to the pyridine ring. This modification endows it with unique chemical properties that make it a valuable intermediate in the synthesis of various compounds.
Uses
Used in Pharmaceutical Industry:
4-Methylnicotinic acid is used as a key intermediate in the synthesis of nicotinic acid substituted nicotinic acid adenine dinucleotide phosphate (NADP) analogs. These analogs are crucial in the development of pharmaceuticals targeting specific metabolic pathways and enzyme activities, potentially leading to treatments for various diseases and conditions.
The unique chemical properties of 4-methylnicotinic acid, including its white powder form and the presence of a methyl group on the pyridine ring, contribute to its versatility and applicability in the synthesis of important biologically active compounds. Its role in the pharmaceutical industry highlights its significance in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 3222-50-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,2,2 and 2 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 3222-50:
(6*3)+(5*2)+(4*2)+(3*2)+(2*5)+(1*0)=52
52 % 10 = 2
So 3222-50-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H7NO2/c1-5-2-3-8-4-6(5)7(9)10/h2-4H,1H3,(H,9,10)
3222-50-2Relevant articles and documents
-
Lounasmaa,M. et al.
, p. 2529 - 2532 (1978)
-
Azaisoquinolinone derivatives as NK3 antagonists
-
, (2013/07/31)
The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS
-
, (2011/10/04)
The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
